Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study (347 views)
Cancer Investigation (ISSN: 0735-7907), 2010 Oct; 28(8): 820-827.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.39, 5-year impact factor: 2.22
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77956636233&partnerID=40&md5=cfaa920f72e7c2bcbd7a5c4ce85c1f61
Keywords: Cisplatin, Esophageal Cancer, Paclitaxel, Preoperative Chemoradiotherapy, Adult, Advanced Cancer, Alopecia, Article, Bronchoscopy, Cancer Combination Chemotherapy, Clinical Article, Clinical Trial, Computer Assisted Tomography, Diarrhea, Esophagitis, Esophagus Cancer, Esophagus Resection, Female, Granulocytopenia, Heart Atrium Fibrillation, Human, Nausea, Neuropathy, Phase 2 Clinical Trial, Positron Emission Tomography, Preoperative Treatment, Priority Journal, Survival Rate, Treatment Outcome, Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Squamous Cell, Combined Modality Therapy, Drug Administration Schedule, Esophageal Neoplasms, Esophagectomy, Middle Aged, Neoplasm Staging, Patient Selection, Platelet Count, Prognosis, Time Factors,
Affiliations:
*** IBB - CNR ***
Division of Medical Oncology, School of Medicine, Second University of Naples, Naples, Italy
Department of Clinical and Experimental Medicine and Surgery F. Magrassi e A. Lanzara, School of Medicine, Second University of Naples, Naples, Italy
Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy
References:
Portale, G., Hagen, J.A., Peters, J.M., Chan, L.S., Demeester, S.R., Gandamihardja, T.A., Demeester, T.R., Modern 5-year survival of resectable esophageal adenocarcinoma: Single institution experience with 263 patients (2006) J Am Coll Surg, 202 (4), pp. 588-59
Bosset, J.F., Lorchel, F., Mantion, G., Buffet, J., Créhange, G., Bosset, G., Chaigneau, L., Servagi, S., Radiation and chemoradiation therapy for esophageal adenocarcinoma (2005) J Surg Oncol, 92, pp. 239-245
Gebski, V., Burmeister, B., Smithers, B.M., Foo, K., Zalcberg, J., Simes, J., Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis (2007) Lancet Oncol., 8, pp. 226-234. , Australasian Gastro-Intestinal Trials Group
Kaklamanos, I.G., Walker, G.R., Ferry, K., Franceschi, D., Livingstone, A.S., Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analyses of randomized clinical trials (2003) Ann Surg Oncol, 10, pp. 754-761
Urschel, J.D., Vasan, H., A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer (2003) Am J Surg, 185, pp. 538-543
Fiorica, F., Di Bona, D., Schepis, F., Licata, A., Shahied, L., Venturi, A., Falchi, A.M., Cammà, C., Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and metaanalyses (2004) Gut, (53), pp. 925-930
De Vita, F., Di Martino, N., Orditura, M., Cosenza, A., Galizia, G., Del Genio, A., Catalano, G., Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: A phase II study (2002) Chest, 122, pp. 1302-1308
Meluch, A.A., Greco, F.A., Gray, J.R., Thomas, M., Sutton, V.M., Davis, J.L., Kalman, L.A., Rinaldi, D.A., Hainsworth, Preoperative therapy with concurrent paclitaxel/ carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: Final results of a Minnie Pearl Cancer Research Network phase II trial (2003) Cancer J, 9, pp. 251-260
Henry, L.R., Goldberg, M., Scott, W., Konski, A., Meropol, N., Freedman, G., Weiner, L.M., Cheng, J.D., Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report (2006) Ann Surg Oncol, 13, pp. 214-220
Roof, K.S., Coen, J., Lynch, T.J., Wright, C., Fidias, P., Willett, C.G., Choi, N.C., Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer (2006) Int J Radiat Oncol Biol Phys, 65, pp. 1120-1128
Lowy, A.M., Firdaus, I., Roychowdhury, D., Redmond, K., Howington, J.A., Sussman, J.J., Safa, M., Jazieh, A.R., A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma (2006) Am J Clin Oncol, 6, pp. 551-561
Van De Schoot, L., Romme, E.A.P.M., Van Dee Sangen, M.J., Creemers, G.J., Van Lijnschoten, G., Van Driel, O.J., Rutten, H.J., Nieuwenhuijzen, G.A., A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer (2008) Ann Surg Oncol, 1, pp. 88-95
Blanke, C.D., Choy, H., Teng, M., Beauchamp, R.D., Leach, S., Roberts, J., Washington, K., Johnson, D.H., Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer (1999) Seminars in Radiation Oncology, 9 (2 SUPPL. 1), pp. 43-52
Urba, S.G., Orringer, M.B., Turrisi, A., Iannettoni, M., Forastiere, A., Strawderman, M., A phase II trial of preoperative cisplatin, paclitaxel, and radiation therapy before trans-hiatal esophagectomy in patients with locoregional esophageal cancer (2001) J Clin Oncol, 19, p. 248
Safran, H., Gaissert, H., Akerman, P., Hesketh, P.J., Chen, M.-H., Moore, T., Koness, J., Wanebo, H.J., Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer (2001) Cancer Investigation, 19 (1), pp. 1-7. , DOI 10.1081/CNV-100000068
Adelstein, D.J., Rice, T.W., Rybicki, L.A., Larto, M.A., Ciezki, J., Saxton, J., Decamp, M., Zuccaro, G., Does paclitaxel improve chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy (2000) J Clin Oncol, 18, pp. 2032-2039
Van Meerten, E., Muller, K., Tilanus, H.W., Siersema, P.D., Eijkenboom, W.M., Van Dekken, H., Tran, T.C., Van Der Gaast, A., Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with esophageal cancer: A phase II study (2006) Br J Cancer, 94, pp. 1389-1394
Boone, J., Livestro, D.P., Elias, S.G., Borel Rinkes, I.H., Van Hillegersberg, R., International survey on esophageal cancer: Part II staging and neoadjuvant therapy (2009) Dis Esophagus, 22 (3), pp. 203-210
Noble, F., Bailey, D., Tung, K., Byrne, J.P., Impact of integrated PET/CT in the staging of oesophageal cancer: A UK population-based cohort study (2009) Clin Radiol, 64 (7), pp. 699-705. , SWCIS Upper Gastrointestinal Tumour Panel
Ngamruengphong, S., Sharma, V.K., Nguyen, B., Das, A., Assessment of response to neoadjuvant therapy in esophageal cancer: An updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography (2009) Dis Esophagus, , Jun 9. [Epub ahead of print]
Jamil, L.H., Gill, K.R., Staging, B.W.M., And restaging of advanced esophageal cancer (2008) Curr Opin Gastroenterol, 24 (4), pp. 530-534
Schneider, P.M., Metzger, R., Schaefer, H., Baumgarten, F., Vallbohmer, D., Brabender, J., Wolfgarten, E., Hoelscher, A.H., Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer (2008) Ann Surg, 248 (6), pp. 902-908
Omloo, J.M., Sloof, G.W., Boellaard, R., Hoekstra, O.S., Jager, P.L., Van Dullemen, H.M., Fockens, P., Van Lanschot, J.J., Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer (2008) Endoscopy, 40 (6), pp. 464-471
Wong, R., Malthaner, R., Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus (Cochrane Review) (2001) The Cochrane Library, (4)
Ajani, J.A., Ilson, D.H., Daugherty, K., Pazdur, R., Lynch, P.M., Kelsen, D.P., Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus (1994) J Natl Cancer Inst, 86, pp. 1086-1091
Rowinsky, E.K., Donehover, R.C., Paclitaxel (Taxol) (1995) N Eng J Med, 332, pp. 1004-1013
Liebermann, J., Cook, J.A., Fisher, J., Teague, D., Mitchell, J.B., In vitro studies of taxol as a radiation sensitizer in human tumor cells (1994) J Natl Cancer Inst, 86, pp. 441-446
Kim, D.W., Blanke, C.D., Wu, H., Shyr, Y., Berlin, J., Beauchamp, R.D., Chakravarthy, B., Phase II study of preoperative paclitaxel/ cisplatin with radiotherapy in locally advanced esophageal cancer (2007) Int J Radiat Oncol Biol Phys, 67, pp. 397-404
Lin, C.C., Hsu, C.H., Cheng, J.C., Wang, H.P., Lee, J.M., Yeh, K.H., Yang, C.H., Lee, Y.C., Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer (2007) Ann Oncol, 18, pp. 93-98
Mandard, A.M., Dalibard, F., Mandard, J.C., Marnay, J., Henry-Amar, M., Petiot, J.F., Roussel, A., Samama, G., Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal cancer (1994) Cancer, 73, pp. 2680-2686
Isenberg, G., Chak, A., Canto, M.I., Levitan, N., Clayman, J., Pollack, B.J., Sivak, M.V., Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation (1998) Gastrointest Endosc, 48, pp. 158-163
Willis, J., Cooper, G.S., Isenberg, G., Sivak, M.V., Levitan, N., Clayman, J., Chak, A., Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma (2002) Gastrointest Endosc, 55, pp. 655-661
Castell, F., Cook, G.J.R., Quantitative techniques in 18FDG-PET scanning in oncology (2008) Br J Cancer, 98, pp. 1597-1601
Dam, H.Q., Manzone, T.M., Sagar, W., Evolving role of 18Ffluorodeoxyglucose positron emission tomography in the management of esophageal carcinoma (2006) Surg Oncol Clin N Am, 15, pp. 733-749
Ott, K., Weber, W., Siewert, J.R., The importance of PET in the diagnosis and response evaluation of esophageal cancer (2006) Dis Esophagus, 19, pp. 433-442
Erasmus, J.J., Munden, R.F., The role of integrated computed tomography positron-emission tomography in esophageal cancer: Staging and assessment of therapeutic response (2007) Semin Radiat Oncol, 17, pp. 29-37
Kleinberg, L., Forastiere, A.A., Chemoradiation in the management of esophageal cancer (2007) J Clin Oncol, 25, pp. 4110-4117
Bosset, J. F., Lorchel, F., Mantion, G., Buffet, J., Cr hange, G., Bosset, G., Chaigneau, L., Servagi, S., Radiation and chemoradiation therapy for esophageal adenocarcinoma (2005) J Surg Oncol, 92, pp. 239-245
Kaklamanos, I. G., Walker, G. R., Ferry, K., Franceschi, D., Livingstone, A. S., Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analyses of randomized clinical trials (2003) Ann Surg Oncol, 10, pp. 754-761
Urschel, J. D., Vasan, H., A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer (2003) Am J Surg, 185, pp. 538-543
Meluch, A. A., Greco, F. A., Gray, J. R., Thomas, M., Sutton, V. M., Davis, J. L., Kalman, L. A., Rinaldi, D. A., Hainsworth, Preoperative therapy with concurrent paclitaxel/ carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: Final results of a Minnie Pearl Cancer Research Network phase II trial (2003) Cancer J, 9, pp. 251-260
Henry, L. R., Goldberg, M., Scott, W., Konski, A., Meropol, N., Freedman, G., Weiner, L. M., Cheng, J. D., Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report (2006) Ann Surg Oncol, 13, pp. 214-220
Roof, K. S., Coen, J., Lynch, T. J., Wright, C., Fidias, P., Willett, C. G., Choi, N. C., Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer (2006) Int J Radiat Oncol Biol Phys, 65, pp. 1120-1128
Lowy, A. M., Firdaus, I., Roychowdhury, D., Redmond, K., Howington, J. A., Sussman, J. J., Safa, M., Jazieh, A. R., A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma (2006) Am J Clin Oncol, 6, pp. 551-561
Blanke, C. D., Choy, H., Teng, M., Beauchamp, R. D., Leach, S., Roberts, J., Washington, K., Johnson, D. H., Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer (1999) Seminars in Radiation Oncology, 9 (2 SUPPL. 1), pp. 43-52
Urba, S. G., Orringer, M. B., Turrisi, A., Iannettoni, M., Forastiere, A., Strawderman, M., A phase II trial of preoperative cisplatin, paclitaxel, and radiation therapy before trans-hiatal esophagectomy in patients with locoregional esophageal cancer (2001) J Clin Oncol, 19, p. 248
Adelstein, D. J., Rice, T. W., Rybicki, L. A., Larto, M. A., Ciezki, J., Saxton, J., Decamp, M., Zuccaro, G., Does paclitaxel improve chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy (2000) J Clin Oncol, 18, pp. 2032-2039
Jamil, L. H., Gill, K. R., Staging, B. W. M., And restaging of advanced esophageal cancer (2008) Curr Opin Gastroenterol, 24 (4), pp. 530-534
Schneider, P. M., Metzger, R., Schaefer, H., Baumgarten, F., Vallbohmer, D., Brabender, J., Wolfgarten, E., Hoelscher, A. H., Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer (2008) Ann Surg, 248 (6), pp. 902-908
Omloo, J. M., Sloof, G. W., Boellaard, R., Hoekstra, O. S., Jager, P. L., Van Dullemen, H. M., Fockens, P., Van Lanschot, J. J., Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer (2008) Endoscopy, 40 (6), pp. 464-471
Ajani, J. A., Ilson, D. H., Daugherty, K., Pazdur, R., Lynch, P. M., Kelsen, D. P., Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus (1994) J Natl Cancer Inst, 86, pp. 1086-1091
Rowinsky, E. K., Donehover, R. C., Paclitaxel (Taxol) (1995) N Eng J Med, 332, pp. 1004-1013
Kim, D. W., Blanke, C. D., Wu, H., Shyr, Y., Berlin, J., Beauchamp, R. D., Chakravarthy, B., Phase II study of preoperative paclitaxel/ cisplatin with radiotherapy in locally advanced esophageal cancer (2007) Int J Radiat Oncol Biol Phys, 67, pp. 397-404
Lin, C. C., Hsu, C. H., Cheng, J. C., Wang, H. P., Lee, J. M., Yeh, K. H., Yang, C. H., Lee, Y. C., Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer (2007) Ann Oncol, 18, pp. 93-98
Mandard, A. M., Dalibard, F., Mandard, J. C., Marnay, J., Henry-Amar, M., Petiot, J. F., Roussel, A., Samama, G., Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal cancer (1994) Cancer, 73, pp. 2680-2686
Dam, H. Q., Manzone, T. M., Sagar, W., Evolving role of 18Ffluorodeoxyglucose positron emission tomography in the management of esophageal carcinoma (2006) Surg Oncol Clin N Am, 15, pp. 733-749
Erasmus, J. J., Munden, R. F., The role of integrated computed tomography positron-emission tomography in esophageal cancer: Staging and assessment of therapeutic response (2007) Semin Radiat Oncol, 17, pp. 29-37
Cancer Investigation (ISSN: 0735-7907), 2010 Oct; 28(8): 820-827.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.39, 5-year impact factor: 2.22
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77956636233&partnerID=40&md5=cfaa920f72e7c2bcbd7a5c4ce85c1f61
Keywords: Cisplatin, Esophageal Cancer, Paclitaxel, Preoperative Chemoradiotherapy, Adult, Advanced Cancer, Alopecia, Article, Bronchoscopy, Cancer Combination Chemotherapy, Clinical Article, Clinical Trial, Computer Assisted Tomography, Diarrhea, Esophagitis, Esophagus Cancer, Esophagus Resection, Female, Granulocytopenia, Heart Atrium Fibrillation, Human, Nausea, Neuropathy, Phase 2 Clinical Trial, Positron Emission Tomography, Preoperative Treatment, Priority Journal, Survival Rate, Treatment Outcome, Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Squamous Cell, Combined Modality Therapy, Drug Administration Schedule, Esophageal Neoplasms, Esophagectomy, Middle Aged, Neoplasm Staging, Patient Selection, Platelet Count, Prognosis, Time Factors,
Affiliations:
*** IBB - CNR ***
Division of Medical Oncology, School of Medicine, Second University of Naples, Naples, Italy
Department of Clinical and Experimental Medicine and Surgery F. Magrassi e A. Lanzara, School of Medicine, Second University of Naples, Naples, Italy
Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy
References:
Portale, G., Hagen, J.A., Peters, J.M., Chan, L.S., Demeester, S.R., Gandamihardja, T.A., Demeester, T.R., Modern 5-year survival of resectable esophageal adenocarcinoma: Single institution experience with 263 patients (2006) J Am Coll Surg, 202 (4), pp. 588-59
Bosset, J.F., Lorchel, F., Mantion, G., Buffet, J., Créhange, G., Bosset, G., Chaigneau, L., Servagi, S., Radiation and chemoradiation therapy for esophageal adenocarcinoma (2005) J Surg Oncol, 92, pp. 239-245
Gebski, V., Burmeister, B., Smithers, B.M., Foo, K., Zalcberg, J., Simes, J., Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis (2007) Lancet Oncol., 8, pp. 226-234. , Australasian Gastro-Intestinal Trials Group
Kaklamanos, I.G., Walker, G.R., Ferry, K., Franceschi, D., Livingstone, A.S., Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analyses of randomized clinical trials (2003) Ann Surg Oncol, 10, pp. 754-761
Urschel, J.D., Vasan, H., A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer (2003) Am J Surg, 185, pp. 538-543
Fiorica, F., Di Bona, D., Schepis, F., Licata, A., Shahied, L., Venturi, A., Falchi, A.M., Cammà, C., Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and metaanalyses (2004) Gut, (53), pp. 925-930
De Vita, F., Di Martino, N., Orditura, M., Cosenza, A., Galizia, G., Del Genio, A., Catalano, G., Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: A phase II study (2002) Chest, 122, pp. 1302-1308
Meluch, A.A., Greco, F.A., Gray, J.R., Thomas, M., Sutton, V.M., Davis, J.L., Kalman, L.A., Rinaldi, D.A., Hainsworth, Preoperative therapy with concurrent paclitaxel/ carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: Final results of a Minnie Pearl Cancer Research Network phase II trial (2003) Cancer J, 9, pp. 251-260
Henry, L.R., Goldberg, M., Scott, W., Konski, A., Meropol, N., Freedman, G., Weiner, L.M., Cheng, J.D., Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report (2006) Ann Surg Oncol, 13, pp. 214-220
Roof, K.S., Coen, J., Lynch, T.J., Wright, C., Fidias, P., Willett, C.G., Choi, N.C., Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer (2006) Int J Radiat Oncol Biol Phys, 65, pp. 1120-1128
Lowy, A.M., Firdaus, I., Roychowdhury, D., Redmond, K., Howington, J.A., Sussman, J.J., Safa, M., Jazieh, A.R., A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma (2006) Am J Clin Oncol, 6, pp. 551-561
Van De Schoot, L., Romme, E.A.P.M., Van Dee Sangen, M.J., Creemers, G.J., Van Lijnschoten, G., Van Driel, O.J., Rutten, H.J., Nieuwenhuijzen, G.A., A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer (2008) Ann Surg Oncol, 1, pp. 88-95
Blanke, C.D., Choy, H., Teng, M., Beauchamp, R.D., Leach, S., Roberts, J., Washington, K., Johnson, D.H., Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer (1999) Seminars in Radiation Oncology, 9 (2 SUPPL. 1), pp. 43-52
Urba, S.G., Orringer, M.B., Turrisi, A., Iannettoni, M., Forastiere, A., Strawderman, M., A phase II trial of preoperative cisplatin, paclitaxel, and radiation therapy before trans-hiatal esophagectomy in patients with locoregional esophageal cancer (2001) J Clin Oncol, 19, p. 248
Safran, H., Gaissert, H., Akerman, P., Hesketh, P.J., Chen, M.-H., Moore, T., Koness, J., Wanebo, H.J., Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer (2001) Cancer Investigation, 19 (1), pp. 1-7. , DOI 10.1081/CNV-100000068
Adelstein, D.J., Rice, T.W., Rybicki, L.A., Larto, M.A., Ciezki, J., Saxton, J., Decamp, M., Zuccaro, G., Does paclitaxel improve chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy (2000) J Clin Oncol, 18, pp. 2032-2039
Van Meerten, E., Muller, K., Tilanus, H.W., Siersema, P.D., Eijkenboom, W.M., Van Dekken, H., Tran, T.C., Van Der Gaast, A., Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with esophageal cancer: A phase II study (2006) Br J Cancer, 94, pp. 1389-1394
Boone, J., Livestro, D.P., Elias, S.G., Borel Rinkes, I.H., Van Hillegersberg, R., International survey on esophageal cancer: Part II staging and neoadjuvant therapy (2009) Dis Esophagus, 22 (3), pp. 203-210
Noble, F., Bailey, D., Tung, K., Byrne, J.P., Impact of integrated PET/CT in the staging of oesophageal cancer: A UK population-based cohort study (2009) Clin Radiol, 64 (7), pp. 699-705. , SWCIS Upper Gastrointestinal Tumour Panel
Ngamruengphong, S., Sharma, V.K., Nguyen, B., Das, A., Assessment of response to neoadjuvant therapy in esophageal cancer: An updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography (2009) Dis Esophagus, , Jun 9. [Epub ahead of print]
Jamil, L.H., Gill, K.R., Staging, B.W.M., And restaging of advanced esophageal cancer (2008) Curr Opin Gastroenterol, 24 (4), pp. 530-534
Schneider, P.M., Metzger, R., Schaefer, H., Baumgarten, F., Vallbohmer, D., Brabender, J., Wolfgarten, E., Hoelscher, A.H., Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer (2008) Ann Surg, 248 (6), pp. 902-908
Omloo, J.M., Sloof, G.W., Boellaard, R., Hoekstra, O.S., Jager, P.L., Van Dullemen, H.M., Fockens, P., Van Lanschot, J.J., Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer (2008) Endoscopy, 40 (6), pp. 464-471
Wong, R., Malthaner, R., Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus (Cochrane Review) (2001) The Cochrane Library, (4)
Ajani, J.A., Ilson, D.H., Daugherty, K., Pazdur, R., Lynch, P.M., Kelsen, D.P., Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus (1994) J Natl Cancer Inst, 86, pp. 1086-1091
Rowinsky, E.K., Donehover, R.C., Paclitaxel (Taxol) (1995) N Eng J Med, 332, pp. 1004-1013
Liebermann, J., Cook, J.A., Fisher, J., Teague, D., Mitchell, J.B., In vitro studies of taxol as a radiation sensitizer in human tumor cells (1994) J Natl Cancer Inst, 86, pp. 441-446
Kim, D.W., Blanke, C.D., Wu, H., Shyr, Y., Berlin, J., Beauchamp, R.D., Chakravarthy, B., Phase II study of preoperative paclitaxel/ cisplatin with radiotherapy in locally advanced esophageal cancer (2007) Int J Radiat Oncol Biol Phys, 67, pp. 397-404
Lin, C.C., Hsu, C.H., Cheng, J.C., Wang, H.P., Lee, J.M., Yeh, K.H., Yang, C.H., Lee, Y.C., Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer (2007) Ann Oncol, 18, pp. 93-98
Mandard, A.M., Dalibard, F., Mandard, J.C., Marnay, J., Henry-Amar, M., Petiot, J.F., Roussel, A., Samama, G., Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal cancer (1994) Cancer, 73, pp. 2680-2686
Isenberg, G., Chak, A., Canto, M.I., Levitan, N., Clayman, J., Pollack, B.J., Sivak, M.V., Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation (1998) Gastrointest Endosc, 48, pp. 158-163
Willis, J., Cooper, G.S., Isenberg, G., Sivak, M.V., Levitan, N., Clayman, J., Chak, A., Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma (2002) Gastrointest Endosc, 55, pp. 655-661
Castell, F., Cook, G.J.R., Quantitative techniques in 18FDG-PET scanning in oncology (2008) Br J Cancer, 98, pp. 1597-1601
Dam, H.Q., Manzone, T.M., Sagar, W., Evolving role of 18Ffluorodeoxyglucose positron emission tomography in the management of esophageal carcinoma (2006) Surg Oncol Clin N Am, 15, pp. 733-749
Ott, K., Weber, W., Siewert, J.R., The importance of PET in the diagnosis and response evaluation of esophageal cancer (2006) Dis Esophagus, 19, pp. 433-442
Erasmus, J.J., Munden, R.F., The role of integrated computed tomography positron-emission tomography in esophageal cancer: Staging and assessment of therapeutic response (2007) Semin Radiat Oncol, 17, pp. 29-37
Kleinberg, L., Forastiere, A.A., Chemoradiation in the management of esophageal cancer (2007) J Clin Oncol, 25, pp. 4110-4117
Bosset, J. F., Lorchel, F., Mantion, G., Buffet, J., Cr hange, G., Bosset, G., Chaigneau, L., Servagi, S., Radiation and chemoradiation therapy for esophageal adenocarcinoma (2005) J Surg Oncol, 92, pp. 239-245
Kaklamanos, I. G., Walker, G. R., Ferry, K., Franceschi, D., Livingstone, A. S., Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analyses of randomized clinical trials (2003) Ann Surg Oncol, 10, pp. 754-761
Urschel, J. D., Vasan, H., A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer (2003) Am J Surg, 185, pp. 538-543
Meluch, A. A., Greco, F. A., Gray, J. R., Thomas, M., Sutton, V. M., Davis, J. L., Kalman, L. A., Rinaldi, D. A., Hainsworth, Preoperative therapy with concurrent paclitaxel/ carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: Final results of a Minnie Pearl Cancer Research Network phase II trial (2003) Cancer J, 9, pp. 251-260
Henry, L. R., Goldberg, M., Scott, W., Konski, A., Meropol, N., Freedman, G., Weiner, L. M., Cheng, J. D., Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report (2006) Ann Surg Oncol, 13, pp. 214-220
Roof, K. S., Coen, J., Lynch, T. J., Wright, C., Fidias, P., Willett, C. G., Choi, N. C., Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer (2006) Int J Radiat Oncol Biol Phys, 65, pp. 1120-1128
Lowy, A. M., Firdaus, I., Roychowdhury, D., Redmond, K., Howington, J. A., Sussman, J. J., Safa, M., Jazieh, A. R., A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma (2006) Am J Clin Oncol, 6, pp. 551-561
Blanke, C. D., Choy, H., Teng, M., Beauchamp, R. D., Leach, S., Roberts, J., Washington, K., Johnson, D. H., Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer (1999) Seminars in Radiation Oncology, 9 (2 SUPPL. 1), pp. 43-52
Urba, S. G., Orringer, M. B., Turrisi, A., Iannettoni, M., Forastiere, A., Strawderman, M., A phase II trial of preoperative cisplatin, paclitaxel, and radiation therapy before trans-hiatal esophagectomy in patients with locoregional esophageal cancer (2001) J Clin Oncol, 19, p. 248
Adelstein, D. J., Rice, T. W., Rybicki, L. A., Larto, M. A., Ciezki, J., Saxton, J., Decamp, M., Zuccaro, G., Does paclitaxel improve chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy (2000) J Clin Oncol, 18, pp. 2032-2039
Jamil, L. H., Gill, K. R., Staging, B. W. M., And restaging of advanced esophageal cancer (2008) Curr Opin Gastroenterol, 24 (4), pp. 530-534
Schneider, P. M., Metzger, R., Schaefer, H., Baumgarten, F., Vallbohmer, D., Brabender, J., Wolfgarten, E., Hoelscher, A. H., Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer (2008) Ann Surg, 248 (6), pp. 902-908
Omloo, J. M., Sloof, G. W., Boellaard, R., Hoekstra, O. S., Jager, P. L., Van Dullemen, H. M., Fockens, P., Van Lanschot, J. J., Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer (2008) Endoscopy, 40 (6), pp. 464-471
Ajani, J. A., Ilson, D. H., Daugherty, K., Pazdur, R., Lynch, P. M., Kelsen, D. P., Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus (1994) J Natl Cancer Inst, 86, pp. 1086-1091
Rowinsky, E. K., Donehover, R. C., Paclitaxel (Taxol) (1995) N Eng J Med, 332, pp. 1004-1013
Kim, D. W., Blanke, C. D., Wu, H., Shyr, Y., Berlin, J., Beauchamp, R. D., Chakravarthy, B., Phase II study of preoperative paclitaxel/ cisplatin with radiotherapy in locally advanced esophageal cancer (2007) Int J Radiat Oncol Biol Phys, 67, pp. 397-404
Lin, C. C., Hsu, C. H., Cheng, J. C., Wang, H. P., Lee, J. M., Yeh, K. H., Yang, C. H., Lee, Y. C., Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer (2007) Ann Oncol, 18, pp. 93-98
Mandard, A. M., Dalibard, F., Mandard, J. C., Marnay, J., Henry-Amar, M., Petiot, J. F., Roussel, A., Samama, G., Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal cancer (1994) Cancer, 73, pp. 2680-2686
Dam, H. Q., Manzone, T. M., Sagar, W., Evolving role of 18Ffluorodeoxyglucose positron emission tomography in the management of esophageal carcinoma (2006) Surg Oncol Clin N Am, 15, pp. 733-749
Erasmus, J. J., Munden, R. F., The role of integrated computed tomography positron-emission tomography in esophageal cancer: Staging and assessment of therapeutic response (2007) Semin Radiat Oncol, 17, pp. 29-37
Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study
We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.
We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.
Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study
No results. |
Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study
Other filter: ([btitle,keywords] "Esophageal Cancer" O ...
Crisci V, Mainenti PP, Corvino F, Lauria R, Maurea S
* Bone involvement by adenocarcinoma of the uterine cervix: a rare entity (284 views)
Pol J Radiol (ISSN: 0137-7183, 1733-134x, 1733-134xlinking), 2015 Feb 14; 80(1): 81-84.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Napolitano M, D'Alterio C, Cardone E, Trotta AM, Pecori B, Rega D, Pace U, Scala D, Scognamiglio G, Tatangelo F, Cacciapuoti C, Pacelli R, Delrio P, Scala S
* Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients (420 views)
Oncotarget (ISSN: 1949-2553, 1949-2553electronic), 2015; 6(10): 8261-8270.
Impact Factor: 5.008
View Export to BibTeX Export to EndNote
Insabato L, Natella V, Somma A, Persico M, Camera L, Losito NS, Masone S
* Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis: A Vexing Issue (300 views)
Int J Surg Pathol (ISSN: 1066-8969), 2015; 23(3): 211-216.
Impact Factor: 0.782
View Export to BibTeX Export to EndNote
Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, Pepe S
* Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications (522 views)
Head Neck-J Sci Spec (ISSN: 1043-3074), 2015; 37(5): 763-770.
Impact Factor: 2.76
View Export to BibTeX Export to EndNote
D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
* A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients (440 views)
Int J Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.
Impact Factor: 5.085
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A, Laterza MM, Ruol A, Fabozzi A, Napolitano V, Iovino F, Lieto E, Fei L, Conzo G, Ciardiello F, De Vita F
* Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study (1872 views)
Curr Oncol (ISSN: 1198-0052, 1718-7729electronic, 1198-0052linking), 2014 Jun; 21(3): 125-133.
Impact Factor: 1.785
View Export to BibTeX Export to EndNote
Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D
* Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs (571 views)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1176-9114linking), 2014 Mar 27; 9(1): 1537-1557.
Impact Factor: 4.383
View Export to BibTeX Export to EndNote
Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A
* Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET (456 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2013 May; 78(5): 760-767.
Impact Factor: 3.353
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (394 views)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
View Export to BibTeX Export to EndNote
Accardo A, Morisco A, Tesauro D, Pedone C, Morelli G
* Naposomes: A new class of peptide-derivatized, target-selective multimodal nanoparticles for imaging and therapeutic applications (408 views)
Ther Deliv (ISSN: 2041-5990), 2011 Feb; 2(2): 235-257.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Di Lorenzo G, Imbimbo M, Leopardo D, Marciano R, Federico P, Buonerba C, Salvatore B, Marinelli A, Palmieri G. A
* A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient (295 views)
Int J Immunopathol Pharmacol (ISSN: 0394-6320), 2010 Jul; 23(3): 951-954.
Impact Factor: 2.685
View Export to BibTeX Export to EndNote
Portella G, Pacelli R, Libertini S, Cella L, Vecchio G, Salvatore M, Fusco A
* ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells (467 views)
J Clin Endocrinol Metab Journal Of Clinical Endocrinology And Metabolism (ISSN: 0021-972x), 2003 Oct 1; 88(10): 5027-5032.
Impact Factor: 5.873
View Export to BibTeX Export to EndNote
Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio MG, Frontini L, Rossi A, Barletta E, Barzelloni ML, Bilancia D, Gallo C
* Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study (255 views) (PDF 220 views)
Br J Cancer (ISSN: 0007-0920print, 0007-0920linking), 2001 Jan 5; 84(1): 38-41.
Impact Factor: 3.942
View Export to BibTeX Export to EndNote
Herscher LL, Cook JA, Pacelli R, Pass HI, Russo A, Mitchell JB
Principles of chemoradiation: Theoretical and practical considerations (406 views)
Oncology (ISSN: 0890-9091), 1999 Oct; 13(10SUPPL.5): 11-22.
Impact Factor: 0.933
View Export to BibTeX Export to EndNote
Del Vecchio S, Mansi L, Petrillo A, Camera L, Sofia M, Marra A, Carratú L, Salvatore M
Endobronchial administration of iodine-131 B72. 3 monoclonal antibody in patients with lung cancer (292 views)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1991; 18(2): 129-132.
Impact Factor: 2.692
View Export to BibTeX Export to EndNote
* Bone involvement by adenocarcinoma of the uterine cervix: a rare entity (284 views)
Pol J Radiol (ISSN: 0137-7183, 1733-134x, 1733-134xlinking), 2015 Feb 14; 80(1): 81-84.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Napolitano M, D'Alterio C, Cardone E, Trotta AM, Pecori B, Rega D, Pace U, Scala D, Scognamiglio G, Tatangelo F, Cacciapuoti C, Pacelli R, Delrio P, Scala S
* Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients (420 views)
Oncotarget (ISSN: 1949-2553, 1949-2553electronic), 2015; 6(10): 8261-8270.
Impact Factor: 5.008
View Export to BibTeX Export to EndNote
Insabato L, Natella V, Somma A, Persico M, Camera L, Losito NS, Masone S
* Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis: A Vexing Issue (300 views)
Int J Surg Pathol (ISSN: 1066-8969), 2015; 23(3): 211-216.
Impact Factor: 0.782
View Export to BibTeX Export to EndNote
Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, Pepe S
* Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications (522 views)
Head Neck-J Sci Spec (ISSN: 1043-3074), 2015; 37(5): 763-770.
Impact Factor: 2.76
View Export to BibTeX Export to EndNote
D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
* A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients (440 views)
Int J Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.
Impact Factor: 5.085
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A, Laterza MM, Ruol A, Fabozzi A, Napolitano V, Iovino F, Lieto E, Fei L, Conzo G, Ciardiello F, De Vita F
* Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study (1872 views)
Curr Oncol (ISSN: 1198-0052, 1718-7729electronic, 1198-0052linking), 2014 Jun; 21(3): 125-133.
Impact Factor: 1.785
View Export to BibTeX Export to EndNote
Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D
* Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs (571 views)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1176-9114linking), 2014 Mar 27; 9(1): 1537-1557.
Impact Factor: 4.383
View Export to BibTeX Export to EndNote
Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A
* Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET (456 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2013 May; 78(5): 760-767.
Impact Factor: 3.353
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (394 views)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
View Export to BibTeX Export to EndNote
Accardo A, Morisco A, Tesauro D, Pedone C, Morelli G
* Naposomes: A new class of peptide-derivatized, target-selective multimodal nanoparticles for imaging and therapeutic applications (408 views)
Ther Deliv (ISSN: 2041-5990), 2011 Feb; 2(2): 235-257.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Di Lorenzo G, Imbimbo M, Leopardo D, Marciano R, Federico P, Buonerba C, Salvatore B, Marinelli A, Palmieri G. A
* A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient (295 views)
Int J Immunopathol Pharmacol (ISSN: 0394-6320), 2010 Jul; 23(3): 951-954.
Impact Factor: 2.685
View Export to BibTeX Export to EndNote
Portella G, Pacelli R, Libertini S, Cella L, Vecchio G, Salvatore M, Fusco A
* ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells (467 views)
J Clin Endocrinol Metab Journal Of Clinical Endocrinology And Metabolism (ISSN: 0021-972x), 2003 Oct 1; 88(10): 5027-5032.
Impact Factor: 5.873
View Export to BibTeX Export to EndNote
Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio MG, Frontini L, Rossi A, Barletta E, Barzelloni ML, Bilancia D, Gallo C
* Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study (255 views) (PDF 220 views)
Br J Cancer (ISSN: 0007-0920print, 0007-0920linking), 2001 Jan 5; 84(1): 38-41.
Impact Factor: 3.942
View Export to BibTeX Export to EndNote
Herscher LL, Cook JA, Pacelli R, Pass HI, Russo A, Mitchell JB
Principles of chemoradiation: Theoretical and practical considerations (406 views)
Oncology (ISSN: 0890-9091), 1999 Oct; 13(10SUPPL.5): 11-22.
Impact Factor: 0.933
View Export to BibTeX Export to EndNote
Del Vecchio S, Mansi L, Petrillo A, Camera L, Sofia M, Marra A, Carratú L, Salvatore M
Endobronchial administration of iodine-131 B72. 3 monoclonal antibody in patients with lung cancer (292 views)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1991; 18(2): 129-132.
Impact Factor: 2.692
View Export to BibTeX Export to EndNote
15 Records (15 excluding Abstracts).
Total impact factor: 41.905 (41.905 excluding Abstracts).
Total 5 year impact factor: 41.118 (41.118 excluding Abstracts).
Total impact factor: 41.905 (41.905 excluding Abstracts).
Total 5 year impact factor: 41.118 (41.118 excluding Abstracts).
347 views. Last view on Tuesday 28 March 2023, 18:39:40
ibb.cnr.it
